Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQIE58)

Drug Name

HH2853 Drug Info

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Enhancer of zeste homolog 1 (EZH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DS-3201b	DMI69E5	T-cell leukaemia	2A90	Phase 2	[3]
DS-3201	DMRLPFG	Acute lymphoblastic leukaemia	2A85	Phase 1	[4]
GSK343	DM9QU5Y	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting Enhancer of zeste homolog 2 (EZH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazemetostat	DMWP1BH	Follicular lymphoma	2A80	Approved	[6]
DS-3201b	DMI69E5	T-cell leukaemia	2A90	Phase 2	[3]
CPI-1205	DM3XWJ8	Prostate cancer	2C82.0	Phase 1/2	[4]
SHR2554	DMMUCH0	Prostate cancer	2C82.0	Phase 1/2	[7]
CPI-0209	DMJEXLI	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
DS-3201	DMRLPFG	Acute lymphoblastic leukaemia	2A85	Phase 1	[4]
GSK2816126	DMJDVW4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PF-06821497	DML3WT6	Diffuse large B-cell lymphoma	2A81	Phase 1	[10]
PMID28394193-Compound-56	DMQRFZK	N. A.	N. A.	Patented	[11]
PMID28394193-Compound-46	DMYMPNA	N. A.	N. A.	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Enhancer of zeste homolog 1 (EZH1)	TTNJA0C	EZH1_HUMAN	Inhibitor	[2]
Enhancer of zeste homolog 2 (EZH2)	TT9MZCQ	EZH2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04390737) Evaluate the Safety and Clinical Activity of HH2853. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of HaiHe Biopharma.
3	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
8	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
9	National Cancer Institute Drug Dictionary (drug id 756211).
10	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
11	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.